Loading...

Bicycle Therapeutics plc

BCYC•NASDAQ
Healthcare
Biotechnology
$4.72
$-0.01(-0.21%)
U.S. Market opens in 14h 28m

Bicycle Therapeutics plc (BCYC) Stock Overview

Explore Bicycle Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap326.9M
P/E Ratio-1.50
EPS (TTM)$-3.16
ROE-0.36%
Fundamental Analysis

AI Price Forecasts

1 Month$2.32
3 Months$9.81
1 Year Target$3.87

BCYC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bicycle Therapeutics plc (BCYC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 44.09, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.87.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.50 and a market capitalization of 326.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.21%
5-Day Change
-1.87%
1-Month Change
8.76%
3-Month Change
-26.48%
6-Month Change
-46.12%
Year-to-Date (YTD) Change
-33.33%
1-Year Change
-44.86%
3-Year Change
-77.16%
5-Year Change
-84.77%
All-Time (Max) Change
-60.67%

Contact Information

https://www.bicycletherapeutics.com
44 1223 261 503
Babraham Research Campus, Cambridge, NaN, CB22 3AT

Company Facts

305 Employees
IPO DateMay 23, 2019
CountryGB
Actively Trading

Frequently Asked Questions